A multinational assessment of complications in type 1 diabetes: the DiaMond substudy of complications (DiaComp) Level 1

Abstract

The objectives of this study were to describe the global geographic variation of microvascular and macrovascular complications in childhood onset type 1 diabetes (T1D) and to relate any such variation to diabetes care activities such as self blood glucose monitoring and intensive insulin therapy.

The DiaComp study is a multinational (17 countries) cross-sectional study of complications in T1D (n=2, 657). All participants were diagnosed at < 15 years of age and had a diabetes duration of 5-24 years when surveyed. Complications were assessed by self-report of physician diagnosis.

Twenty-two centres in 17 countries achieved at least a 67% response rate and are included in the analyses. Central European centres exhibited high rates of retinopathy (Lithuania=31. 6%, Romania=24. 2%), laser treatment (Lithuania=25. 4%) and neuropathy (Lithuania=29. 9%, Romania=12. 4%) in those with short duration of diabetes (5–15 years), as did Cuba for neuropathy (15. 4%). For retinopathy the geographic variation in the short-duration group was also pronounced, ranging from 1. 6% in Italy to 41. 6% in Lithuania, and from 0% in Brazil, Italy and Australia, to 29. 9% in Lithuania for laser treatment. Variation was less dramatic for the prevalence of complications in the long-duration group (15–25 years). Hypertension and duration were strong consistent predictors of all complications, while women had higher prevalence for half the complications (retinopathy, laser treatment and renal disease). Intensive insulin therapy and self-monitoring of blood glucose showed little association with prevalence of complications.

In conclusion, this first population-based account of the geographic variation of T1D complications has demonstrated substantial variation. However, the healthcare practice variables that were measured contributed little toward explaining this variation.

Keywords

diabetes treatment complications

References

1. Sochett E , Daneman D Early diabetes related complications in children and adolescents with type 1 diabetes. Implications for screening and intervention. Endocrinol Metab Clin Am 1999;28:865–82.

2. Karvonen M , Viik-Kajander M , Moltchanova E , Libman I , LaPorte R , Tuomilehto J . Incidence of childhood type 1 diabetes worldwide. Diabetes Care 2000;23:1516–26.

3. Lee ET , Keen H , Bennett PH , Fuller JH , Lu M , The WHO Multinational Study Group. Follow-up of the WHO multinational study of vascular disease in diabetes: General description and morbidity. Diabetologia 2001;44(2):3–13.

4. Stephenson J , Fuller JH Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 1994;37:278–85.

5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus . The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–86.

6. Karter AJ , Ackerson LM , Darbinian JA et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med 2001;111 (1):1–9.

7. Coster S , Gulliford MC , Seed PT , Powrie JK , Swaminathan R Self-monitoring in type 2 diabetes mellitus: a meta-analysis. Diabet Med 2000;17:755–61.

8. Harris MI , Hadden WC , Knowler WC , Bennett PH International criteria for the diagnosis of diabetes and impaired glucose tolerance. Diabetes Care 1985;8:562–7.

9. Wagner DK , Sacks JM , Laporte RE , MacGregor JM The Pittsburgh study of insulin-dependent diabetes mellitus: risk for diabetes among relatives of IDDM. Diabetes 1982;31:136–44.

10.

10. Feldman EL , Stevens MJ , Thomas PK , Brown MB , Canal N , Greene DA A practical two-step quantitative clinical electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17:1281–90.

11.

11. Rose GA. The diagnosis of ischemic heart pain and intermittent claudi-cation in field surveys. Bull World Health Organization 1962;42:385–94.

12.

12. Bergmann MM , Byers T , Freedman DS , Mokdad A Validity of self-reported diagnosis leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults. Am J Epidemiol 1998;147:969–77.

13.

13. Kehoe R , Wu SY , Leske MC , Chylack LT Comparing self-reported and physician reported medical history. Am J Epidemiol 1994;139:813–18.

14.

14. Walsh MG , Zgibor J , Borch-Johnsen K , Orchard TJ . A multinational comparison of complications assessment in type 1 diabetes: The DiaMond sub-study of complications (DiaComp) level 2. Diabetes Care 2004;27:1610–17.

15.

15. Cohen RA , Hennekens CH , Christen WG et al. Determinants of retinopathy progression in type 1 diabetes. Am J Med 1999;107(1):45–51.

16.

16. Keen H , Lee ET , Russell D , Miki E , Bennett PH , Lu M , The WHO Multinational Study Group. The appearance of retinopathy and progression to proliferative retinopathy: The WHO multinational study of vascular disease in diabetes. Diabetologia 2001;44(2):22–30.

17.

17. Krolewski AS , Warram JH , Cupples A , Gorman CK , Szabo AJ , Christlieb AR Hypertension, orthostatic hypotension and the microvascular complications of diabetes. J Chronic Dis 1985;38:319–26.

18.

18. Forrest K , Maser RE , Pambianco G , Becker DJ , Orchard TJ Hypertension as a risk factor for diabetic neuropathy. A prospective study. Diabetes 1997;46:665–70.

19.

19. American Diabetes Association. Tests of glycemia in diabetes. Diabetes Care 2003;26(suppl 1):S106–S108.

20.

20. Toeller M , Buyken AE , Heitkamp G , Berg G , Scherbaum WA , The EURODIAB Complications Study Group. Prevalence of chronic complications, metabolic control and nutritional intake in type 1 diabetes: Comparison between different European regions. Horm Metab Res 1999;31:680–5.